IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v6y2015i1d10.1038_ncomms7715.html
   My bibliography  Save this article

Triaminopyrimidine is a fast-killing and long-acting antimalarial clinical candidate

Author

Listed:
  • Shahul Hameed P.

    (AstraZeneca India Pvt. Ltd.)

  • Suresh Solapure

    (AstraZeneca India Pvt. Ltd.)

  • Vikas Patil

    (AstraZeneca India Pvt. Ltd.)

  • Philipp P. Henrich

    (Columbia University Medical Center)

  • Pamela A. Magistrado

    (Harvard School of Public Health)

  • Sowmya Bharath

    (AstraZeneca India Pvt. Ltd.)

  • Kannan Murugan

    (AstraZeneca India Pvt. Ltd.)

  • Pavithra Viswanath

    (AstraZeneca India Pvt. Ltd.)

  • Jayashree Puttur

    (AstraZeneca India Pvt. Ltd.)

  • Abhishek Srivastava

    (AstraZeneca India Pvt. Ltd.)

  • Eknath Bellale

    (AstraZeneca India Pvt. Ltd.)

  • Vijender Panduga

    (AstraZeneca India Pvt. Ltd.)

  • Gajanan Shanbag

    (AstraZeneca India Pvt. Ltd.)

  • Disha Awasthy

    (AstraZeneca India Pvt. Ltd.)

  • Sudhir Landge

    (AstraZeneca India Pvt. Ltd.)

  • Sapna Morayya

    (AstraZeneca India Pvt. Ltd.)

  • Krishna Koushik

    (AstraZeneca India Pvt. Ltd.)

  • Ramanatha Saralaya

    (AstraZeneca India Pvt. Ltd.)

  • Anandkumar Raichurkar

    (AstraZeneca India Pvt. Ltd.)

  • Nikhil Rautela

    (AstraZeneca India Pvt. Ltd.)

  • Nilanjana Roy Choudhury

    (AstraZeneca India Pvt. Ltd.)

  • Anisha Ambady

    (AstraZeneca India Pvt. Ltd.)

  • Radha Nandishaiah

    (AstraZeneca India Pvt. Ltd.)

  • Jitendar Reddy

    (AstraZeneca India Pvt. Ltd.)

  • K. R. Prabhakar

    (AstraZeneca India Pvt. Ltd.)

  • Sreenivasaiah Menasinakai

    (AstraZeneca India Pvt. Ltd.)

  • Suresh Rudrapatna

    (AstraZeneca India Pvt. Ltd.)

  • Monalisa Chatterji

    (AstraZeneca India Pvt. Ltd.)

  • María Belén Jiménez-Díaz

    (Tres Cantos Medicines Development Campus. Diseases of Developing World (DDW), GlaxoSmithKline)

  • María Santos Martínez

    (Tres Cantos Medicines Development Campus. Diseases of Developing World (DDW), GlaxoSmithKline)

  • Laura María Sanz

    (Tres Cantos Medicines Development Campus. Diseases of Developing World (DDW), GlaxoSmithKline)

  • Olivia Coburn-Flynn

    (Columbia University Medical Center)

  • David A. Fidock

    (Columbia University Medical Center
    Columbia University Medical Center)

  • Amanda K. Lukens

    (Harvard School of Public Health)

  • Dyann F. Wirth

    (Harvard School of Public Health)

  • Balachandra Bandodkar

    (AstraZeneca India Pvt. Ltd.)

  • Kakoli Mukherjee

    (AstraZeneca India Pvt. Ltd.)

  • Robert E. McLaughlin

    (AstraZeneca Infection Innovative Medicines)

  • David Waterson

    (Medicines for Malaria Venture, International Center Cointrin)

  • Lyn Rosenbrier-Ribeiro

    (AstraZeneca)

  • Kevin Hickling

    (AstraZeneca)

  • V. Balasubramanian

    (AstraZeneca India Pvt. Ltd.)

  • Peter Warner

    (AstraZeneca India Pvt. Ltd.)

  • Vinayak Hosagrahara

    (AstraZeneca India Pvt. Ltd.)

  • Adam Dudley

    (AstraZeneca India Pvt. Ltd.)

  • Pravin S. Iyer

    (AstraZeneca India Pvt. Ltd.)

  • Shridhar Narayanan

    (AstraZeneca India Pvt. Ltd.)

  • Stefan Kavanagh

    (AstraZeneca)

  • Vasan K. Sambandamurthy

    (AstraZeneca India Pvt. Ltd.
    Present address: Mazumdar Shaw Center for Translational Research (MSCTR), Bangalore, India)

Abstract

The widespread emergence of Plasmodium falciparum (Pf) strains resistant to frontline agents has fuelled the search for fast-acting agents with novel mechanism of action. Here, we report the discovery and optimization of novel antimalarial compounds, the triaminopyrimidines (TAPs), which emerged from a phenotypic screen against the blood stages of Pf. The clinical candidate (compound 12) is efficacious in a mouse model of Pf malaria with an ED99

Suggested Citation

  • Shahul Hameed P. & Suresh Solapure & Vikas Patil & Philipp P. Henrich & Pamela A. Magistrado & Sowmya Bharath & Kannan Murugan & Pavithra Viswanath & Jayashree Puttur & Abhishek Srivastava & Eknath Be, 2015. "Triaminopyrimidine is a fast-killing and long-acting antimalarial clinical candidate," Nature Communications, Nature, vol. 6(1), pages 1-11, November.
    • Handle: RePEc:nat:natcom:v:6:y:2015:i:1:d:10.1038_ncomms7715
    DOI: 10.1038/ncomms7715
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/ncomms7715
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/ncomms7715?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Mariska Naude & Ashleigh van Heerden & Janette Reader & Mariëtte van der Watt & Jandeli Niemand & Dorè Joubert & Giulia Siciliano & Pietro Alano & Mathew Njoroge & Kelly Chibale & Esperanza Herreros &, 2024. "Eliminating malaria transmission requires targeting immature and mature gametocytes through lipoidal uptake of antimalarials," Nature Communications, Nature, vol. 15(1), pages 1-15, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:6:y:2015:i:1:d:10.1038_ncomms7715. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.